Hugoton Royalty Trust
09/20/2024 | Press release | Distributed by Public on 09/20/2024 06:14
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
09/20/2024 | Press release | Distributed by Public on 09/20/2024 06:14
Please select the service you want to use:
Smartlinks | Hugoton Royalty Trust | Finance | Security Markets | Derivative Securities | Security Markets | Company News | Financial Services | Investment Services | Securities Issuers | Investment Trusts | Berlin Stock Exchange | OTC Markets
Back
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact